Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

6
114
0

Year Published

2008
2008
2017
2017

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 198 publications
(120 citation statements)
references
References 45 publications
6
114
0
Order By: Relevance
“…A 2A and NR2B receptor antagonists both show anti-parkinsonian activity in preclinical models; however, the effects are weaker in magnitude compared with dopamine agonists or L-Dopa [14][15][16]34]. A 2A antagonists have also demonstrated weak efficacy in clinical trials when tested as monotherapy in PD patients [22].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…A 2A and NR2B receptor antagonists both show anti-parkinsonian activity in preclinical models; however, the effects are weaker in magnitude compared with dopamine agonists or L-Dopa [14][15][16]34]. A 2A antagonists have also demonstrated weak efficacy in clinical trials when tested as monotherapy in PD patients [22].…”
Section: Discussionmentioning
confidence: 99%
“…A 2A antagonists have been shown to be efficacious against haloperidolinduced catalepsy [16,20,50] and showed positive effects in the forepaw stepping test in unilaterally 6-OHDA lesioned rats [51] and in the rotarod test [52]. However, most studies failed to demonstrate a significant effect of A 2A receptor antagonists on the level of contralateral rotation in lesioned rats in the absence of L-Dopa [14][15][16]53]. To our knowledge, this is the first time that the efficacy of A 2A receptor antagonists on motor activity has been systematically evaluated in unilaterally 6-OHDA-lesioned rats by measuring the general level of motor activity.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The A 2A receptors are colocalized with D2 receptors on medium spiny neurons of the indirect pathway, and antagonists decrease sensitivity to dopaminergic stimulation. 142 One double-blind, placebo-controlled trial demonstrated a decrease in off time by as much as 1.7 hours, compared with placebo, at doses of 20 mg and 40 mg per day. 143 The drug has the potential to prevent dyskinesia, but does not reverse dyskinesia that is already present.…”
Section: Discussionmentioning
confidence: 99%
“…143 The drug has the potential to prevent dyskinesia, but does not reverse dyskinesia that is already present. 142,143 A newer highly selective A 2A antagonist, SCH 420814, is currently being examined in phase II trials.…”
Section: Discussionmentioning
confidence: 99%